Monday, April 15

17:00 – 17:55
Registration & welcome


17:55 – 18:00
Opening
 

Jos Jonkers (The Netherlands Cancer Institute, Amsterdam, NL)


18:00 – 19:00
Keynote Lecture 1
 

Chair: Jos Jonkers (The Netherlands Cancer Institute, Amsterdam, NL)


 
Jeffrey M. Rosen (Baylor College of Medicine, Houston, US)
 

Leveraging preclinical models of breast cancer


19:00 – 20:00
Opening Reception


20:00
Dinner

Tuesday, April 16

07:30 – 08:30
Breakfast


08:30 – 10:00

Session 1: Hormones and Breast Cancer

Chair: Cathrin Brisken (Ecole Polytechnique Fédérale, Lausanne, CH)


08:30 – 09:00

Myles Brown (Dana-Farber Cancer Institute, Boston, US)

Essential genes and cistromes regulating breast cancer hormone dependence


09:00 – 09:30

Luca Magnani (Imperial College, London, UK)

Diving into the dark matter of the breast cancer genome


09:30 – 10:00

Joyce M Slingerland (University of Miami Miller School of Medicine, Miami, US)

Estrone cooperates with the NFkB pathway to promote obesity-driven inflammation and postmenopausal ER+ breast cancer progression


10:00 – 10:20
Coffee Break


10:20 – 11:50

Session 2: In vitro and in vivo models of Breast Cancer

Chair: Mohamed Bentires-Alj (University of Basel, Basel, CH)


10:20 – 10:50

Senthil Muthuswamy (Beth Israel Deaconess Medical Center, Boston, US)

Cell polarity proteins, patient derived organoids and endocrine resistance


10:50 – 11:20

Carol Sartorius (University of Colorado, Aurora, US)

Progestin action in luminal and luminobasal models of breast cancer


11:20 – 11:50

Cathrin Brisken (Ecole Polytechnique Fédérale, Lausanne, CH)

Humanizing the mouse mammary gland to study hormone-dependent breast carcinogenesis


12:10 – 16:55
Visit to the Keukenhof tulips park (with lunch) or lunch and free time


17:15 – 18:45

Session 3: Signaling pathway crosstalk

Chair: Jean J. Zhao (Dana-Farber Cancer Institute, Boston, US)


17:15 – 17:45
Christopher Lord (The Institute of Cancer Research, London, UK)

17:45 – 18:15

René Bernards (Netherlands Cancer Institute, Amsterdam, NL)

Exploiting senescence for cancer therapy


18:15 – 18:45

William J. Muller (Rosalind and Morris Goodman Cancer Center, Montreal, CA)

Evaluating the role of Integrin signaling in breast cancer dormancy


19:00 – 20:00
Dinner


20:00 – 22:00
Poster Session 1 (odd numbers) with drinks

Wednesday, April 17

07:30 – 09:00
Breakfast


09:00 – 10:30

Session 4: Breast cancer genomics and evolution

Chair: William J. Muller (Rosalind and Morris Goodman Cancer Centre, Montreal, CA)


09:00 – 09:30

Carlos Caldas (Cancer Research UK Cambridge Institute, Cambridge, UK)

Know thy enemy: Landscapes of lethal breast cancer


09:30 – 10:00

Steffi Oesterreich (University of Pittsburgh, Pittsburgh, US)

Estrogen receptor mutations


10:00 – 10:30

Mohamed Bentires-Alj (University of Basel, Basel, CH)

Cancer targeted therapy and tumor heterogeneity: Act locally, think globally


10:30 – 11:00
Coffee Break


11:00 – 13:00
Session 5: Immuno-oncology

11:00 – 11:30

Karin E. de Visser (Netherlands Cancer Institute, Amsterdam, NL)

The genetic makeup of primary breast cancer dictates pro-metastatic systemic inflammation


11:30 – 12:00

Jean Zhao (Dana-Farber Cancer Institute, Boston, US)

Integrating immunotherapy and targeted therapies in cancer treatment: from mouse models to human therapies


12:00 – 12:30

Kornelia Polyak (Dana-Farber Cancer Institute, Boston, US)

Immunotherapies and immunoprevention in breast cancer


12:30 – 13:00

Morag Park (Rosalind and Morris Goodman Cancer Center, Montreal, CA)

Functional heterogeneity of the triple-negative breast cancer microenvironment


13:00 – 14:00
Lunch


14:00 – 16:00
Poster Session 2 (even numbers)


16:00 – 17:30

Session 6: Mammary gland biology and stem cells

Chair: Edith C. Kordon (IFIBYNE-UBA-CONICET, University of Buenos Aires, Buenos Aires, AR)


16:00 – 16:30

Alexandra Van Keymeulen (Université Libre de Bruxelles, Bruxelles, BE)

Multipotency and lineage segregation of mammary stem cells


16:30 – 17:00

Silvia Fre (Institut Curie, Paris, FR)

New approaches to study mammary cell fate specification during embryonic morphogenesis


17:00 – 17:30

Jacco van Rheenen (Netherlands Cancer Institute, Amsterdam, NL)

Dissection of the cellular composition of breast tumors for optimal treatment selection


17:30 – 18:20

Proffered abstracts session 1

Chair: Kornelia Polyak (Dana-Farber Cancer Institute, Boston, US)


17:30 – 17:50

Walid T. Khaled (University of Cambridge, Cambridge, UK)

Building a Comprehensive Human Breast Cell Atlas and studying early stages of TNBC by using scRNAseq


17:50 – 18:05

Kienan I. Savage (Queen’s University Belfast, Belfast, UK)

Topoisomerase II inhibitors enhance STING-dependent cytokine release and immune checkpoint activation


18:05 – 18:20

Robert Clarke (University of Manchester, Manchester, UK)

Regulation of breast cancer stem cell activity by the bone metastatic niche


19:00 – 21:00
Conference Dinner at the Ritz

Thursday, April 18

07:30 – 09:00
Breakfast


09:00 – 10:30
Session 7: Translational research

09:00 – 09:30

Matthew J. Ellis (Baylor College of Medicine, Houston, US)

Endocrine Therapy Resistance: new insights


09:30 – 10:00
Judy E. Garber (Dana-Farber Cancer Institute, Boston, US)

10:00 – 10:30

Geoffrey Lindeman (Walter and Eliza Hall Institute of Medical Research, Parkville, AU)

Targeting cell survival pathways in breast cancer using BH3 mimetics


10:30 – 11:00
Coffee Break


11:00 – 11:45

Proffered abstracts session 2

Chair: Robert Clarke (University of Manchester, Manchester, UK)


11:00 – 11:15

Gastón Soria (Universidad Nacional de Córdoba, Córdoba, AR)

Polo-like Kinase 1 inhibition as a novel therapeutic approach to target BRCA1-deficient cancer cells by synthetic lethality induction


11:15 – 11:30

Jennifer K. Richer (University of Colorado, Aurora, US)

Clinical biopsies and preclinical models reveal new therapeutic targets in estrogen receptor mutant metastatic breast cancer


11:30 – 11:45

Douglas Perkins (The Institute of Cancer Research, London, UK)

A role for senescent fibroblasts in breast cancer metastasis


11:45 – 12:00
Coffee Break


12:00 – 13:00
Keynote Lecture 2
 

Chair: John Hilkens (The Netherlands Cancer Institute, Amsterdam, NL)


 
Hans Clevers (Hubrecht Institute, Utrecht, NL)
 

Lgr5 Stem Cell-based organoids in human disease


13:00 – 15:00
Lunch and Departure